
Braftovi and Erbitux Plus Chemo Improves Outcomes for BRAF V600E+ mCRC
Updated data from the phase 3 BREAKWATER trial showed that combining Braftovi (encorafenib) and Erbitux (cetuximab) with mFOLFOX6 chemotherapy (modified fluorouracil, leucovorin and oxaliplatin) elicited a statistically significant and clinically …